Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncopeptides AB ( (SE:ONCO) ) just unveiled an announcement.
Oncopeptides AB has announced a partially guaranteed rights issue of approximately SEK 150 million to support the commercialization of its cancer therapy, Pepaxti, in Europe and to advance its pre-clinical assets. The company is also progressing in partnership negotiations with Japanese pharmaceutical companies for the licensing of Pepaxti in Japan, with advanced discussions and non-binding offers received from potential partners. This strategic move aims to ensure financial stability and expand market reach, potentially leading to significant growth opportunities.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for challenging cancer treatments. Founded 25 years ago, the company operates in key European markets such as Germany, Austria, Spain, and Italy.
Average Trading Volume: 4,992,271
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.13B
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.